Correlation Between Visual Reading and DOlab Software Quantitative Analysis of DaT-SPECT Images
Pre-market Clinical Investigation to Evaluate the Correlation Between Visual Interpretation and Quantitative Analysis Performed by DOlab Software - DaT-SPECT Workflow for the Identification of Neurological Disorders Related to Dopamine Transporter Dysfunction
The goal of this study is to find out whether the quantitative results of DOlab software (DaT-SPECT workflow) agree with the visual reading of brain scans performed by nuclear medicine physicians. The scans are 123I-ioflupane DaT-SPECT images of adults who were evaluated for dopamine transporter dysfunction, a condition seen in Parkinson's disease, other parkinsonian syndromes and dementia with Lewy bodies.
The main questions it aims to answer are:
- Do the visual scores given by expert readers (0 = normal to 3 = marked abnormality) correlate with the values calculated by the software?
- Does using the software report change or refine the readers' classification compared with visual reading alone?
- How usable do readers find the software?
The study uses existing scans of 120 patients collected between January 2015 and May 2025 at two Italian hospitals. No new tests or treatments are given to participants, and the software results are not used for their clinical care.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
Dopamine transporter (DaT) SPECT with 123I-ioflupane is widely used to support the diagnosis of neurological disorders associated with nigrostriatal dopaminergic degeneration. Visual reading by trained physicians is the clinical standard, and semi-quantitative analysis is recommended by the EANM/SNMMI guidelines as an objective complement, especially in borderline cases.
DOlab software - DaT-SPECT workflow (Dorian Technologies; investigational, not CE-marked, class IIa) iteratively maps each scan to MNI space with adaptive volumes of interest for the right and left caudate, anterior putamen and posterior putamen, plus an occipital reference region. It computes four metrics: striatal binding ratio (SBR), Southampton SBR, Basal Ganglia V3 and Volume Fraction. The results are compared with a normative database derived from the Parkinson's Progression Markers Initiative (PPMI) and reported as z-scores.
This is a blinded, multicenter, retrospective investigation at two Italian sites. At each site, an independent reader selects 15 consecutive scans for each visual grade (0, 1, 2, 3), for a total of 120 scans. The images are pseudonymized and uploaded to a shared repository.
Phase 1: four independent readers (two per site), blinded to all clinical information except sex and age, visually score the randomized images (0-3) for the caudate, anterior putamen and posterior putamen of each hemisphere. In parallel, the software analyzes the same images, and the visual scores are correlated with the software metrics.
Phase 2: the images are re-randomized and re-coded, and the same readers perform a semi-quantitative assessment supported by the software report. Classifications from the two phases are then compared. Finally, the readers complete the System Usability Scale (SUS).
Sample size: 85 subjects are needed to detect a correlation of 0.30 (two-sided alpha 0.05, power 80%). 120 subjects are planned to allow for non-evaluable images.
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Paolo Bosco
- Número de teléfono: +39 320 070 6224
- Correo electrónico: paolo.bosco@dorian-tech.com
Ubicaciones de estudio
-
-
Tuscany
-
Prato, Tuscany, Italia, 59100
- Reclutamiento
- Azienda USL Toscana Centro - Ospedale Santo Stefano
-
Investigador principal:
- Stelvio Sestini, MD
-
-
Veneto
-
Padova, Veneto, Italia, 35128
- Reclutamiento
- Azienda Ospedale Università Padova
-
Investigador principal:
- Diego Cecchin, MD
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Adults referred for evaluation of nigrostriatal dopaminergic dysfunction who underwent 123I-ioflupane DaT-SPECT between January 2015 and May 2025 at Santo Stefano Hospital (Prato) or the University Hospital of Padua, Italy. At each center, 15 consecutive scans per visual grade (negative, mild, moderate and marked abnormality) are selected retrospectively.
Descripción
Inclusion Criteria:
- Age 18 years or older.
- Referred for evaluation of nigrostriatal dopaminergic dysfunction to one of the participating centers between January 2015 and May 2025.
- Informed consent for data collection, or documentation that all reasonable efforts to obtain consent were made (Italian Privacy Code, art. 110).
- 123I-ioflupane SPECT images that:
- were acquired according to the PPMI imaging protocol;
- have a field of view covering the entire head, from the superior cortical regions to the lower cerebellum;
- followed the radiotracer manufacturer's acquisition timing and methods;
- were attenuation-corrected according to local standard procedures.
Exclusion Criteria:
- Age under 18 years.
- Use of drugs or substances that may significantly affect DaT binding (e.g., cocaine, amphetamines, CNS stimulants, opioid derivatives, antidepressants, adrenergic agonists, anticholinergics, anesthetics) without a washout of at least five biological half-lives before DaT-SPECT, per the EANM/SNMMI guidelines.
- DaT-SPECT performed outside the January 2015 - May 2025 period.
- Images not meeting the acquisition and quality specifications listed above.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: CASE_ONLY
- Perspectivas temporales: RETROSPECTIVE
Número de grupos/cohortes
Cohortes e Intervenciones
Grupo / CohorteGrupo / Cohorte |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Adults referred for DaT-SPECT
Adults referred for evaluation of nigrostriatal dopaminergic dysfunction at the two participating centers between January 2015 and May 2025, whose existing 123I-ioflupane DaT-SPECT scans were selected retrospectively (30 per visual grade 0-3, 15 per grade per center). Each scan is read visually by four blinded readers, analyzed by DOlab software, and then re-read with the software report. |
Investigational software (not CE-marked, class IIa) that automatically quantifies striatal 123I-ioflupane binding using four metrics (SBR, Southampton SBR, Basal Ganglia V3, Volume Fraction) and compares them with a PPMI-based normative database. It is applied retrospectively to existing images, and its output is not used for patient care. Visual reading of the same 123I-ioflupane images by blinded nuclear medicine physicians, scored 0-3 for the caudate, anterior putamen and posterior putamen of each hemisphere, according to the EANM/SNMMI guidelines. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Correlation between visual score and DOlab quantitative metrics
Periodo de tiempo: Phase 1 reading session, within 4 months of study start
|
Pearson correlation coefficient (with 95% CI) between the readers' visual score (ordinal 0-3; 0 = normal, 3 = marked abnormality) and each continuous metric produced by DOlab software (SBR, Southampton SBR, Basal Ganglia V3, Volume Fraction) for the caudate, anterior putamen and posterior putamen of each hemisphere. If the Pearson assumptions are not met, the Spearman rank correlation is reported. |
Phase 1 reading session, within 4 months of study start
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Agreement between visual and software-supported semi-quantitative classification
Periodo de tiempo: Phase 2 reading session, within 4 months of study start
|
Cohen's kappa coefficient between the classifications given by the same readers with visual reading alone (Phase 1) and with the DOlab software report (Phase 2). |
Phase 2 reading session, within 4 months of study start
|
|
Number of scans reclassified with software support
Periodo de tiempo: Phase 2 reading session, within 4 months of study start
|
Number and percentage of scans whose classification changes between visual reading alone and software-supported reading (e.g., borderline to abnormal), tested with McNemar's test for paired proportions. |
Phase 2 reading session, within 4 months of study start
|
|
Software usability (System Usability Scale)
Periodo de tiempo: After the Phase 2 reading session, within 4 months of study start
|
SUS questionnaire completed by the 4 readers: 10 items on a 5-point scale. SUS total score from 0 to 100, where higher scores indicate better perceived usability; item responses are also reported as median and IQR. |
After the Phase 2 reading session, within 4 months of study start
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Investigador principal: Stelvio Sestini, MD, Azienda USL Toscana Centro - Santo Stefano Hospital, Prato
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Sinucleinopatías
- Enfermedades Cerebrales
- Enfermedades del Sistema Nervioso Central
- Enfermedades del Sistema Nervioso
- Desordenes mentales
- Trastornos neurocognitivos
- Demencia
- Enfermedades neurodegenerativas
- Enfermedades de los ganglios basales
- Trastornos del movimiento
- Enfermedad de Parkinson
- Enfermedad de cuerpos de Lewy
- Trastornos Parkinsonianos
Otros números de identificación del estudio
Otros números de identificación del estudio
- Dorian-2025
- IT-26-01-056194 (Otro identificador: EUDAMED (Italian Ministry of Health))
- 29262_spe (Otro identificador: Comitato Etico Regione Toscana - Area Vasta Centro)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Individual participant data and images will not be shared, because the clinical investigation plan restricts data use to the sponsor and investigators and the dataset includes pseudonymized imaging data of patients who could not all be reconsented. Aggregate results will be published.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .